MedTrace Logo

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

NCT02648997 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-26

Study results available
· View outcomes & findings →

Summary

This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.

Conditions

Interventions

DRUG

Nivolumab - 240 mg

240 mg every 2 weeks

DRUG

Ipilimumab - 1 mg/kg

1 mg/kg every 3 weeks

DRUG

Nivolumab - 480 mg

480 mg once every 4 weeks

DRUG

Nivolumab - 3 mg/kg

3 mg/kg every 3 weeks

RADIATION

External Beam RT

IMRT, 3D-CRT, or proton-beam radiation therapy

DRUG

Nivolumab - 1 mg/kg

1 mg/kg every 3 weeks

DRUG

Ipilimumab - 3 mg/kg

3 mg/kg every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • David A Reardon, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2024-12-01
Completion
2026-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648997 on ClinicalTrials.gov